This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a retrospective cohort study, which was carried out in a single centre. The patients were allocated to the study groups on the basis of patient preferences and the judgement of a transfusion medicine physician. The patients were not followed after receiving the transplant.
Analysis of effectiveness
All of the patients included in the initial study sample were considered in the effectiveness analysis. The health outcomes used in the analysis were: the use of RBC units, PABD RBC units, allogeneic RBC units, or salvaged RBC units; the distribution of the average percentage of PABD units transfused per cardiac transplant patient; the total number of autologous units produced and transfused; and the trend in autologous donations.
The study groups were comparable at baseline in terms of their age and gender, but differences were noted in the mean pre-operative haemoglobin level and type of disease.
Effectiveness results
The total RBC units were 10.3 (+/-7.2) in the PABD group and 10.5 (+/-5.8) in the no PABD group, (p=0.834). The allogeneic RBC units were 5 (+/-5.4) in the PABD and 7.13 (+/-4.8) in the no PABD group, (p=0.02). The salvaged RBC units were 2.3 (+/-3.4) in the PABD group and 3.4 (+/-2.5) in the no PABD group, (p=0.0021).
The distribution of the average percentage of PABD units transfused per cardiac transplant patient was 28% PABD, 49% allogeneic and 23% salvaged in the PABD group, and 68% allogeneic and 32% salvaged in the no PABD group.
The total number of autologous units produced over the whole study period was 423 in the PABD group (average 5.1 +/-1.5 units per patient), where 23% of the patients were transfused with autologous blood only. However, only 251 units were actually used. In terms of the trend in autologous donations, a mean of 21.58 (+/-4) PABD units per year were collected at the study clinic. The numbers peaked in 1990 and 1991, but after 1995 there was a decrease in PABDs and in 1999 only one PABD was actually transfused.
Clinical conclusions
The effectiveness study showed that PADB represented an alternative and safe approach for preoperative transfusion in patients undergoing heart transplants.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used. A cost-consequences analysis was therefore conducted.
Direct costs
Discounting was not performed since the costs per patient were incurred in a short time period. The unit costs were reported separately from the quantities of resources used. The health services in the economic evaluation were for PABD and allogeneic transfusion. These included testing, processing and labelling, as well as the recruitment of donors and collections for allogeneic transfusion. In addition, the costs of freezing and thawing the units were also considered. The costs of compatibility testing and blood component administration were not included. The cost/resource boundary adopted in the study appears to have been that of the hospital. The costs and resource use were estimated using data coming from the in-house work-load and cost-accounting data at the study hospital. The price year was not reported.
